CDK9 Inhibitor Compound Structure for Selective Antitumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK9 inhibitors exhibit limitations in efficacy, selectivity, and safety, necessitating the development of novel compounds with improved in vivo antitumor activity and reduced toxicity.
Innovation Solution
A compound represented by formula (I) or its pharmaceutically acceptable salt, stereoisomer, or prodrug, which acts as a CDK9 inhibitor, featuring specific structural components such as X, R1, R2, and Ring A, designed to enhance CDK9 inhibitory activity, selectivity, and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK9 inhibitors are used, then CDK9 inhibitory activity is achieved, but in vivo antitumor activity is insufficient and toxicity is high
Solution Approach 1:
The patent modifies the chemical structure of CDK9 inhibitors by changing parameters such as introducing specific substituent groups (R1, R2, R3, R4), adjusting ring structures (Ring A, Ring B), and modifying linker regions to optimize the balance between antitumor activity and toxicity. This structural parameter optimization enables the compound to achieve superior in vivo antitumor activity while reducing toxic side effects compared to existing inhibitors.
Solution Approach 2:
The patent introduces different substituent groups at specific positions of the molecule (R1, R2, R3, R4) to create local structural variations that enhance target selectivity and reduce off-target toxicity. By optimizing local chemical environments at different regions of the inhibitor molecule, the compound achieves improved therapeutic index through enhanced antitumor activity while minimizing harmful effects on non-target tissues.
2Reliability
If existing CDK9 inhibitors are used, then some inhibitory activity is achieved, but selectivity for CDK9 over other CDKs is insufficient
Solution Approach 1:
The patent introduces specific substituent groups (R1, R2, R3, R4) at defined positions of the inhibitor molecule to create local structural features that enhance selectivity for CDK9 over other CDK isoforms. These local modifications optimize interactions with CDK9-specific residues in the binding pocket while reducing affinity for other CDKs, thereby achieving high selectivity without sacrificing overall inhibitory activity.
Solution Approach 2:
The patent employs asymmetric structural design in the inhibitor molecule, particularly in the arrangement of substituent groups and ring structures, to match the asymmetric binding site of CDK9. This asymmetric configuration enables selective recognition and binding to CDK9, distinguishing it from other CDK isoforms with different binding site geometries, thus achieving high selectivity while maintaining potent inhibitory activity.
Data Source
AI summary
Disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotope derivative or a prodrug thereof. The compound has an excellent activity as a cyclin-dependent kinase 9 (CDK9) inhibitor for treating hyperproliferative diseases. The experimental research on in vitro inhibition of cell proliferation and in vivo suppression of tumors shows that such compounds have a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and have a good selectivity and a low toxicity and few side effects, thereby possessing a good clinical value as novel anti-tumor drugs.